AstraZeneca plc (AZN) Shares Bought by Creative Planning

Creative Planning boosted its holdings in AstraZeneca plc (NYSE:AZN) by 10.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,639 shares of the company’s stock after buying an additional 4,357 shares during the period. Creative Planning’s holdings in AstraZeneca were worth $1,733,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Primecap Management Co. CA boosted its stake in AstraZeneca by 4.5% in the 3rd quarter. Primecap Management Co. CA now owns 55,399,286 shares of the company’s stock worth $2,192,150,000 after buying an additional 2,364,013 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of AstraZeneca by 106.2% in the 3rd quarter. Jennison Associates LLC now owns 39,744,304 shares of the company’s stock valued at $1,572,682,000 after purchasing an additional 20,470,137 shares in the last quarter. FMR LLC lifted its stake in shares of AstraZeneca by 74.5% in the 3rd quarter. FMR LLC now owns 35,325,790 shares of the company’s stock valued at $1,397,841,000 after purchasing an additional 15,082,609 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of AstraZeneca by 10.7% in the 4th quarter. Fisher Asset Management LLC now owns 14,965,240 shares of the company’s stock valued at $568,380,000 after purchasing an additional 1,448,516 shares in the last quarter. Finally, Capital International Investors lifted its stake in shares of AstraZeneca by 3.4% in the 3rd quarter. Capital International Investors now owns 9,752,587 shares of the company’s stock valued at $385,910,000 after purchasing an additional 319,416 shares in the last quarter. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on the company. HSBC reaffirmed a “sell” rating on shares of AstraZeneca in a research note on Monday, November 12th. Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Monday, November 12th. UBS Group reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Monday, November 19th. Investec lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Monday, November 19th. Finally, Goldman Sachs Group reaffirmed a “sell” rating on shares of AstraZeneca in a research note on Friday, November 16th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $45.50.

AstraZeneca stock opened at $37.01 on Friday. The company has a market cap of $93.57 billion, a P/E ratio of 8.65, a P/E/G ratio of 1.96 and a beta of 0.51. The company has a current ratio of 0.86, a quick ratio of 0.66 and a debt-to-equity ratio of 1.36. AstraZeneca plc has a one year low of $32.69 and a one year high of $41.78.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.33 by $0.38. The firm had revenue of $5.34 billion for the quarter, compared to analyst estimates of $5.26 billion. AstraZeneca had a return on equity of 27.32% and a net margin of 11.29%. AstraZeneca’s revenue for the quarter was down 14.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 EPS. Sell-side analysts expect that AstraZeneca plc will post 1.64 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Shares Bought by Creative Planning” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2019/02/09/astrazeneca-plc-azn-shares-bought-by-creative-planning.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Understanding Analyst Ratings

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit